<DOC>
	<DOC>NCT02545075</DOC>
	<brief_summary>The purpose of this study is to determine whether Ipilimumab will extend the life of chinese patients with Chemotherapy Naive Stage IV Melanoma more than Dacarbazine as well as to examine safety in this patient population.</brief_summary>
	<brief_title>A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Chinese males and females ≥ 18 years of age Histologic diagnosis of malignant melanoma Chemotherapy naive Stage IV melanoma (AJCC 2010) Life expectancy of ≥ 16 weeks Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Evidence of brain metastases on brain imaging Primary ocular or mucosal melanoma Any other malignancy from which the patient has been diseasefree for less than 5 years BRAF status cannot be determined by Screening test Human Immunodeficiency Virus (HIV) positive or hepatitis B surface antigen (HBsAg) positive, or active Hepatitis C infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>